851 Enhancing cancer immunotherapy with Deinococcus geothermalis in combination with PD-1 inhibitors: a novel strategy for non-small cell lung cancer treatment

Benzer Materyaller

• Circulating low-density neutrophils as biomarkers of resistance to first-line anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer
  Yazar:: N Castro, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-05-01)
• Peripheral inflammatory factors as prognostic predictors for first-line PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer
  Yazar:: Chen-xing Jin, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-04-01)
• T Cell Invigoration is Associated with the Clinical Response to Anti-PD-1-Based Immunotherapy in Non-Small Cell Lung Cancer
  Yazar:: Wu H, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-10-01)
• Research trends and highlights in PD-1/PD-L1 inhibitor immunotherapy in lung cancer: a bibliometric analysis
  Yazar:: Zheng Gu, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-03-01)
• Efficacy and safety of PD‐1/PD‐L1 inhibitors in elderly patients with advanced non‐small cell lung cancer
  Yazar:: Li Li, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-05-01)